291 related articles for article (PubMed ID: 31555275)
1. TRAIL-Receptor 4 Modulates γδ T Cell-Cytotoxicity Toward Cancer Cells.
Tawfik D; Groth C; Gundlach JP; Peipp M; Kabelitz D; Becker T; Oberg HH; Trauzold A; Wesch D
Front Immunol; 2019; 10():2044. PubMed ID: 31555275
[TBL] [Abstract][Full Text] [Related]
2. Regulatory Interactions Between Neutrophils, Tumor Cells and T Cells.
Oberg HH; Wesch D; Kalyan S; Kabelitz D
Front Immunol; 2019; 10():1690. PubMed ID: 31379875
[TBL] [Abstract][Full Text] [Related]
3. Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against γδ T cell cytotoxicity.
Gonnermann D; Oberg HH; Kellner C; Peipp M; Sebens S; Kabelitz D; Wesch D
Oncoimmunology; 2015 Mar; 4(3):e988460. PubMed ID: 25949900
[TBL] [Abstract][Full Text] [Related]
4. NKG2D regulates production of soluble TRAIL by ex vivo expanded human γδ T cells.
Dokouhaki P; Schuh NW; Joe B; Allen CA; Der SD; Tsao MS; Zhang L
Eur J Immunol; 2013 Dec; 43(12):3175-82. PubMed ID: 24019170
[TBL] [Abstract][Full Text] [Related]
5. Celastrol increases osteosarcoma cell lysis by γδ T cells through up-regulation of death receptors.
Li Z; Zhang J; Tang J; Wang R
Oncotarget; 2016 Dec; 7(51):84388-84397. PubMed ID: 27768597
[TBL] [Abstract][Full Text] [Related]
6. Novel bispecific antibodies increase γδ T-cell cytotoxicity against pancreatic cancer cells.
Oberg HH; Peipp M; Kellner C; Sebens S; Krause S; Petrick D; Adam-Klages S; Röcken C; Becker T; Vogel I; Weisner D; Freitag-Wolf S; Gramatzki M; Kabelitz D; Wesch D
Cancer Res; 2014 Mar; 74(5):1349-60. PubMed ID: 24448235
[TBL] [Abstract][Full Text] [Related]
7. Influence of Indoleamine-2,3-Dioxygenase and Its Metabolite Kynurenine on γδ T Cell Cytotoxicity against Ductal Pancreatic Adenocarcinoma Cells.
Jonescheit H; Oberg HH; Gonnermann D; Hermes M; Sulaj V; Peters C; Kabelitz D; Wesch D
Cells; 2020 May; 9(5):. PubMed ID: 32384638
[TBL] [Abstract][Full Text] [Related]
8. Isopentenyl pyrophosphate-activated CD56+ {gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma.
Alexander AA; Maniar A; Cummings JS; Hebbeler AM; Schulze DH; Gastman BR; Pauza CD; Strome SE; Chapoval AI
Clin Cancer Res; 2008 Jul; 14(13):4232-40. PubMed ID: 18594005
[TBL] [Abstract][Full Text] [Related]
9. Endogenous TRAIL-R4 critically impacts apoptotic and non-apoptotic TRAIL-induced signaling in cancer cells.
Rambow AC; Aschenbach I; Hagelund S; Tawfik D; Gundlach JP; Weiße S; Maass N; Trauzold A
Front Cell Dev Biol; 2022; 10():942718. PubMed ID: 36158196
[TBL] [Abstract][Full Text] [Related]
10. Tumor resistance mechanisms and their consequences on γδ T cell activation.
Wesch D; Kabelitz D; Oberg HH
Immunol Rev; 2020 Nov; 298(1):84-98. PubMed ID: 33048357
[TBL] [Abstract][Full Text] [Related]
11. Killing of laminin receptor-positive human lung cancers by tumor infiltrating lymphocytes bearing gammadelta(+) t-cell receptors.
Ferrarini M; Heltai S; Pupa SM; Mernard S; Zocchi R
J Natl Cancer Inst; 1996 Apr; 88(7):436-41. PubMed ID: 8618235
[TBL] [Abstract][Full Text] [Related]
12. TRAIL-R4 promotes tumor growth and resistance to apoptosis in cervical carcinoma HeLa cells through AKT.
Lalaoui N; Morlé A; Mérino D; Jacquemin G; Iessi E; Morizot A; Shirley S; Robert B; Solary E; Garrido C; Micheau O
PLoS One; 2011; 6(5):e19679. PubMed ID: 21625476
[TBL] [Abstract][Full Text] [Related]
13. Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human gammadelta T cells.
Shojaei H; Oberg HH; Juricke M; Marischen L; Kunz M; Mundhenke C; Gieseler F; Kabelitz D; Wesch D
Cancer Res; 2009 Nov; 69(22):8710-7. PubMed ID: 19887600
[TBL] [Abstract][Full Text] [Related]
14. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of gammadelta T cell-induced human oligodendrocyte cytotoxicity: relevance to multiple sclerosis.
Zeine R; Pon R; Ladiwala U; Antel JP; Filion LG; Freedman MS
J Neuroimmunol; 1998 Jul; 87(1-2):49-61. PubMed ID: 9670845
[TBL] [Abstract][Full Text] [Related]
16. Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo.
Kabelitz D; Wesch D; Pitters E; Zöller M
J Immunol; 2004 Dec; 173(11):6767-76. PubMed ID: 15557170
[TBL] [Abstract][Full Text] [Related]
17. Defective gammadelta T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients.
Gaafar A; Aljurf MD; Al-Sulaiman A; Iqniebi A; Manogaran PS; Mohamed GE; Al-Sayed A; Alzahrani H; Alsharif F; Mohareb F; Ajarim D; Tabakhi A; Al-Hussein K
Exp Hematol; 2009 Jul; 37(7):838-48. PubMed ID: 19446661
[TBL] [Abstract][Full Text] [Related]
18. Effect of 4,5-diazafluorene derivative on γδ T cell-mediated cytotoxicity against renal cell carcinoma.
Wen X; Wu Y; Tanaka Y; Awadasseid A; Tao H; Zhang W
Life Sci; 2021 Mar; 269():119066. PubMed ID: 33460663
[TBL] [Abstract][Full Text] [Related]
19. Tribody [(HER2)
Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
Front Immunol; 2018; 9():814. PubMed ID: 29725336
[TBL] [Abstract][Full Text] [Related]
20. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition.
Wrobel P; Shojaei H; Schittek B; Gieseler F; Wollenberg B; Kalthoff H; Kabelitz D; Wesch D
Scand J Immunol; 2007; 66(2-3):320-8. PubMed ID: 17635809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
